Novo Nordisk will apply Dicerna Pharmaceuticals’ GalXC™ platform to discover and develop RNA interference (RNAi) therapies for liver-related cardio-metabolic diseases, including chronic liver diseases, nonalcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and unspecified rare diseases, through a collaboration that could generate more than $3.8 billion for Dicerna. [NIH]
Novo Nordisk will apply Dicerna Pharmaceuticals’ GalXC™ platform to discover and develop RNA interference (RNAi) therapies for liver-related cardio-metabolic diseases, including chronic liver diseases, nonalcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and unspecified rare diseases . . .
![Lilly will transition diabetes drug to Amylin for global development and commercialization.[evgenyb - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Nov8_2011_2346720_DiabetesFingerPrickCloseUp_AmylinLillyEndDiabetesPartnership7811414319-100x70.jpg "Amylin to Pay Lilly $250M to End Exenatide Partnership and Litigation")
